Nephroapp
Exam Cases MCQ Bank

Search

Find tools, topics, and resources

Welcome to Nephroapp
Sign in to keep your progress and bookmarks.
Log in Create account
Explore
Exam cases MCQ Bank Topics Plans and pricing
App
Explore NephroApp
Exam Cases MCQ Bank

Study

Exam cases
MCQ Bank
Fast Recaps
Plans and pricing
‹ Exam Cases
Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step
Drill map
Fast Recap Spoken approach Quick reference Exam traps & pitfalls Guideline algorithm Algorithm 1 master approach diagram Time since transplant Algorithm 2 by time since transplant diagram Pre renal renal post renal Algorithm 3 pre renal and vascular diagram Algorithm 4 post renal and collections diagram Algorithm 5 day 1 oliguria and dgf diagram Algorithm 6 renal causes and biopsy diagram How to read the tests Algorithm 7 rejection treatment diagram Algorithm 8 infection BK CMV pyelonephritis diagram Algorithm 9 late graft dysfunction diagram Algorithm 10 unknown donor or no biopsy diagram Treatment by cause Memorise treatment and escalation Examiner follow-ups Go deeper
Exam tools
Study
📋Topics 🎯By branch
🎯 NephroApp · Exam Cases
Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step
nephroapp.com
🔥 #6 most asked · 20 sittings · 32× Transplant KDIGO KTR 2009 + Banff Viva: all algorithms

Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step

By Dr. Hossam Abohassan · Updated Nov 7, 2026

Graft dysfunction = AKI in a single kidney on immunosuppression. Stabilise and dialyse if needed, then let time since transplant rank the causes, sort them pre-renal, post-renal, renal, exclude dehydration, obstruction and a high CNI level (Doppler + trough + BK/CMV PCR + DSA), and biopsy any persistent unexplained rise before treating rejection. Treat the biopsy, not the creatinine.

Practise 1 MCQ on this topicExam-style questions with explanations →

Watch & listen to this topic

🎬 Full video · the whole approach, animated

Open on YouTube ↗

⚡ NephroApp short · 2 min summary

Your browser does not support audio playback.

🎧 Full podcast

Your browser does not support audio playback.

🎧 Full podcast

Your browser does not support audio playback.
Exam links & past questions
📌 Exam topic #6 · Antibody-mediated rejection (ABMR/AMR, Banff) 20 sittings · 32×
Also on this exam topic: Exam caseAntibody-Mediated Rejection (ABMR) TopicAntibody-Mediated Rejection: Steroids, Plasma Exchange, IVIG and Rituximab TopicAntibody-Mediated Rejection: Refractory Cases and Q&A TopicAcute Graft Dysfunction After the First Year: Rejection, CNI Toxicity or BK TopicAcute graft dysfunction: a systematic approach from CNI level, Doppler and BK PCR to biopsy
🪜 Treatment ladder: Antibody-mediated rejection (ABMR)
⚖️ Comparison tables: BK nephropathy vs ABMR vs TCMR (biopsy) Banff ABMR: active vs chronic active vs chronic Banff TCMR grades: borderline, I, II, III Hyperacute vs accelerated rejection vs DGF
🎯 Asked in the real exam · 21 reports — answer each aloud
  1. Hyperacute rejection: treatment.Oct 2026
  2. Session 2 also included membranous nephropathy (25y, normal kidney, proteinuria 5g - investigations before biopsy then biopsy shows MN - treatment); and antibody-mediated rejection with tacrolimus level 4, month 6 - treatment.Jan 2026
  3. Q5: Stable transplant, slowly rising creatinine 1-2 years - approachSep 2025
  4. ABMR: renal biopsy findings and treatment in order with doses (steroid then plasmapheresis then IVIG).May 2025
  5. Acute antibody-mediated rejection treatment plus diagnosis; and treatment of BK nephropathy (patient on Cellcept 2 gm, Tac level 9).Apr 2025
  6. Topic list: ABMR Rx; immunoglobulin side effects; Banff classification.Apr 2025
  7. Antibody-mediated rejection treatment regimen including steroid type; and how many plasma exchange sessionsFeb 2025
  8. Transplant patient with rejection; biopsy shows tubulitis + interstitial inflammation, no C4d, no DSA — diagnosis and treatmentFeb 2025
  9. Session 2: acute ABMR treatment; back pain + macro hematuria + proteinuria (DD renal vein thrombosis vs stone); hyponatremia 113 with malignancy/pleural effusion; criteria & causes of SIADH; SIADH Na 127 approach; early & late donor complications; EPS risk factors and treatment; indication for catheter removal; pregnant IgA nephropathy treatment (ACR >50, normal eGFR).Dec 2024
  10. Committee 2 list (4 Qs): ABMR; hyperkalemia; diabetic CKD with persistent albuminuria; hematuria in 70-year-old with glomerular source.Dec 2024
  11. T-cell-mediated rejection — Banff classification and treatment; allograft dysfunction 8 hours after operation.Aug 2024
  12. Committee 2: ABMR; Hyperkalemia; Diabetes CKD with persistent albuminuria; Hematuria in 70yo, glomerular source (4 questions). A colleague was asked about study supporting SGLT2 in CKD.Jul 2024
  13. Transplant patient with antibody-mediated rejection: Banff classification, C4d, and management.Jul 2024
  14. Difficult Tx/biopsy questions: (1) differentiate BK nephropathy vs acute AMR on biopsy; (2) Tx pt with BK infection + suspected rejection, no biopsy possible — management; (3) 30F fever + graft tenderness 1yr post-Tx, DDx & management; (4) CRRT citrate anticoagulation with filter clotting — action; (5) membranous nephropathy not responding to steroids, refusing cyclophosphamide/CNI — next option.Oct 2023
  15. Son potential kidney donor to father (ESRD); father has DSA MFI 4000 pre-Tx but crossmatch negative — approach? Accept donor? Desensitization protocol?Oct 2023
  16. Antibody-mediated rejection: renal biopsy findings; treatment in order with doses (steroid then plasmapheresis then IVIG).Sep 2023
  17. Transplant patient at 3 months with rising creatinine; biopsy = ABMR — risk factors for ABMR and treatment.
  18. Cellular rejection: pathognomonic histology and Banff classification; treatment for Banff 1
  19. Antibody-mediated acute rejection: treatment; do you use glucocorticoids and why
  20. Acute antibody-mediated rejection (AMR): diagnosis and management
  21. Transplantation: ABMR; management - donor-specific antibody daily (?) +++
📌 Exam topic #28 · Delayed graft function / day-1 oliguria 5 sittings · 13×
Also on this exam topic: Exam caseDelayed Graft Function / Day-1 Oliguria TopicDelayed graft function after kidney transplant: ATN, risk factors and when to biopsy TopicOliguria on Day Zero After Kidney Transplant: Surgical vs Medical Causes TopicComplete Anuria After Kidney Transplant: Emergency Surgical Work-up
🪜 Treatment ladder: Delayed graft function
⚖️ Comparison tables: Hyperacute vs accelerated rejection vs DGF ATN/DGF vs vascular thrombosis vs obstruction Arterial vs venous thrombosis vs obstruction vs urine leak
🎯 Asked in the real exam · 9 reports — answer each aloud
  1. Delayed graft function (def; causes duration management).
  2. Acute graft dysfunction (early cpc) - differential dg.
  3. Anuria after 6 hours of kidney transplantation — your approach?
  4. Delayed graft function => cellular (rejection).
  5. What is delayed graft function and how to manage
  6. Transplant patient with rising creatinine - turned out to be CMV infection
  7. Delayed graft function: definition, causes, duration, management
  8. Acute graft dysfunction (early complications): differential diagnosis and management
  9. Creatinine rises 1 week after kidney transplantation: what is the cause?
📌 Exam topic #42 · Commercial transplant abroad — returning with graft dysfunction 2 sittings · 8×
Also on this exam topic: Exam caseCommercial Transplant Abroad — Returning with Graft Dysfunction TopicAcute Kidney Injury Five Days After a Kidney Bought Abroad Exam caseAntibody-Mediated Rejection (ABMR)
🎯 Asked in the real exam · 6 reports — answer each aloud
  1. Commercial transplant abroad with creatinine 700 µmol/L and no donor or transplant data; Doppler normal, dialysis already started: what next?Oct 2026
  2. Transplant abroad, 48h later in ER with Cr 400 and anuria; biopsy = antibody-mediated rejection — urgent indication for dialysis, stabilize, then AMR management (plasma exchange, steroids, IVIG)Mar 2026
  3. Q8: KTX abroad 1 week ago, ER creat 200, stable - approach (Banff 2b, DSA)Sep 2025
  4. Commercial transplant patient from abroad (Uzbekistan), ~4-7 days post-op: approach to early graft dysfunction; pitfall of saying 'donor-specific antibody' when donor unknown; biopsy when platelets low.Jul 2024
  5. Patient who had illegal commercial transplant abroad (Pakistan), presents ~1 week post-op with creatinine 190, unknown baseline/donor/induction: approach to graft dysfunction (early post-transplant AKI).Jan 2024
  6. 35yo, transplant abroad (presumed commercial donor), presents day 5 post-transplant, no donor work-up, on steroid/MMF/tacrolimus, Cr 550: how to investigate and treat
Fast Recap · 7 stops

Graft dysfunction at a glance

AKI in a single kidney on immunosuppression. Stabilise, rank by time, exclude reversible causes, then biopsy.

  1. Stabilise first Dialyse if needed; keep immunosuppression on.
  2. Time ranks causes Hours, week 1, 12 weeks, later.
  3. pre renal post Sort the compartments Exclude volume, obstruction, high trough.
  4. Biopsy, then treat Treat the biopsy, not the creatinine.
1 Stabilisation 2 Time since transplant 3 DGF 4 Pre- and post-renal 5 Renal causes and biopsy 6 Rejection 7 Infection and late
  1. 1

    Stop 1 · Emergency

    Initial assessment and stabilisation

    Treat the life threats; keep immunosuppression running.

    K⁺ keep IS
    • Hyperkalaemia, acidosis, overload, uraemia: urgent dialysis
    • Gentle ultrafiltration, never aggressive
    • Continue immunosuppression
    History

    Adherence, missed doses, new interacting drugs, diarrhoea, fever, urine output, donor and induction.

    Examination

    Volume, graft tenderness, wound, drain, Foley.

    Memory hook

    “Some Fluid Drains Through Plastic Bags”

    Sstabilise FFoley + fluids DDoppler Ttrough PPCR + DSA Bbiopsy
  2. 2

    Stop 2 · Differential

    Differential diagnosis by time since transplant

    The clock ranks the causes before any test.

    8 h wk 1 12 wk 3–12 mo >1 yr
    Within 8 hours
    Hyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion.
    Doppler now; absent flow = re-exploration.
    Week 1
    ATN/DGF (commonest), accelerated rejection, obstruction or leak, thrombosis, volume contraction.
    Up to 12 weeks
    Acute rejection, CNI toxicity, obstruction, pyelonephritis or viral infection, interstitial nephritis, recurrence (FSGS in the first month).
    3–12 months
    BK nephropathy (peak 3–6 months), TCMR, CMV, TRAS, lymphocele.
    Over 1 year
    Non-adherence, de novo DSA → chronic active ABMR; chronic CNI toxicity, recurrent GN, TRAS, PTLD.
    Memory hook

    TCMR: usually after week 1, most often within 3–6 months.

  3. 3

    Stop 3 · Early graft

    Day-1 oliguria and delayed graft function

    Foley, fluids, Doppler; only then presumed ATN.

    Day 1 72 h 1–2 weeks
    1. 1 · Flush the Foley

      Blocked or kinked catheter first.

    2. 2 · Fluid challenge

      Reassess volume status.

    3. 3 · Renal Doppler

      Thrombosis, obstruction or leak: urgent re-exploration or urologic intervention.

    Artery thrombosis

    0.1–2%, within 72 h, painless anuria.
    Vein: haematuria, oliguria, pain, no venous flow.

    Definitions

    DGF: dialysis within the first week.
    Slow graft function: creatinine >3 mg/dL (~265 µmol/L), no dialysis.

    Presumed ATN

    Continue immunosuppression, check trough, dialysis as needed; no aggressive UF.
    Furosemide 100–200 mg only if hypervolaemic.

    Rising or beyond 1–2 weeks

    Biopsy for rejection on ATN (most centres 7–10 days); send CMV PCR.

    Exam trap

    Stopping immunosuppression for DGF or dialysis: continue it.

  4. 4

    Stop 4 · Exclusion

    Pre-renal and post-renal causes

    Exclude dehydration, obstruction and a high CNI level first.

    TRAS 1–3 wk Foley
    Pre-renal
    • Hypovolaemia, sepsis: crystalloid (preferred to albumin), stop nephrotoxins.
    • High trough: CNI vasoconstriction; find the CYP3A4 inhibitor, reduce.
    • TRAS (1–23%, first year): Doppler → MRI → angioplasty ± stent.

    Normal RI with falling urine output: haemodynamic cause.

    Post-renal
    • Blocked or kinked Foley: flush.
    • Ureteral obstruction (2–10%, within 3 months): ischaemic stricture commonest.
    • Significant hydronephrosis: nephrostomy or stent → surgical reconstruction.

    Perigraft collections

    Urine leak
    Fluid creatinine well above serum; first 3 months. Foley at once, drain, stent + Foley 1–3 weeks; cystogram before catheter out. Fails: nephrostomy, reimplant.
    Lymphocele
    Creatinine like serum; weeks to months; commoner with mTOR inhibitors. Drain if it compresses.
    Haematoma
    Early or after biopsy; usually resolves.
    Abscess
    Fever, CRP, positive culture: drain + antibiotics.
    Exam trap

    Mild hydronephrosis is often non-significant: the graft ureter has no valve; renogram first.

  5. 5

    Stop 5 · Diagnosis

    Renal causes and allograft biopsy

    Persistent unexplained rise: biopsy before treating rejection (KDIGO 9.1, 6.1).

    >100 platelets C4d SV40
    • Tacrolimus trough
    • Urinalysis, culture, protein
    • Plasma BK and CMV PCR
    • DSA (anti-HLA screen if donor unknown)
    • TMA screen: platelets, LDH, haptoglobin, film
    Doppler Resistive index
    ~0.6 normal, >0.7 high; rejection, ATN, thrombosis, hydronephrosis all raise it.
    Tacrolimus Trough
    High: toxicity likely. Low: missed doses or interaction, rejection risk.
    Typical targets: month 1 10–15, to ~6 months 8–12, later 6–8 (centre-dependent). True trough 12 ± 2 h post-dose.
    Plasma PCR BK virus
    >1,000 copies/mL beyond 2 weeks: probable.
    >10,000: presumptive BK nephropathy.
    Banff biopsy Lesions
    TCMR IA/IB: tubulitis + interstitial inflammation; intimal arteritis IIA/IIB; transmural III.
    Active ABMR: g+ptc + C4d, or g+ptc ≥2 + DSA; cg >0: chronic active.
    BK: SV40-positive inclusions. CNI: isometric vacuolisation; arteriolar hyalinosis, striped fibrosis.

    Biopsy safety: platelets >100, PT and APTT <1.2 × control, BP <140/90, sterile urine.
    Unsafe: correct first, or empirical pulse steroid if rejection likely.

    Exam trap

    High resistive index ≠ rejection: ATN, thrombosis and hydronephrosis raise it too.

  6. 6

    Stop 6 · Treatment

    Treatment of acute rejection

    Treat the biopsy, not the creatinine; grade decides.

    MP 3–5 d rATG 7–14 d S → A → R
    1. TCMR borderline with dysfunction, IA/IB

      Methylprednisolone 3–5 mg/kg (250–500 mg) IV × 3–5 days; optimise trough and adherence; add MMF (Rec 6.5).

    2. TCMR IIA–III or steroid-resistant

      rATG 1–1.5 mg/kg × 7–14 days; IIA–III: start with pulse steroid + rATG.
      After ATG: CMV and PJP prophylaxis, BK plasma PCR monitoring.

    3. Active ABMR

      PLEX 2–5 + IVIG 100–200 mg/kg after each + pulse steroid.

      Refractory, tertiary only: rituximab 375 mg/m² (RCT n=38 negative) or bortezomib 1.3 mg/m² × 4 (BORTEJECT negative).

    Mixed: TCMR by grade + PLEX, IVIG, consider rituximab.
    Chronic active ABMR: optimise tacrolimus, MMF, adherence; no proven reversal.
    No response: repeat biopsy.

    No biopsy possible

    E.g. platelets 20: methylprednisolone 500 mg × 3; correct platelets.
    ~60–70% respond within 5 days; no response: urgent biopsy or transfer.

    Unknown donor

    Anti-HLA antibody screen, not DSA; C4d substitutes on biopsy.
    Screen HBV, HCV, HIV, TB.

    Memory hook

    TCMR = S-A-R: Steroid → ATG → Re-biopsy.
    ABMR = PIS, then R, then B: PLEX + IVIG + Steroid → Rituximab → Bortezomib.

  7. 7

    Stop 7 · Infection and follow-up

    Infection and late graft dysfunction

    Infections need less immunosuppression; late loss starts with adherence.

    BK ≥50% ↓ 10× fall by 4 wk
    1. BK nephropathy · Half, Halt, then CNI

      Antimetabolite down ≥50% → no 10-fold fall at 4 weeks: stop it, prednisone 5–10 mg/day → lower CNI (trough ~5) → re-biopsy.

      CNI-first equally acceptable (2024 BK consensus). IVIG, cidofovir, leflunomide unproven.

    2. CMV disease

      Valganciclovir 900 mg BID or IV ganciclovir 5 mg/kg q12h, GFR-adjusted; reduce antimetabolite.
      Weekly PCR; no response after 2 weeks: UL97/UL54, maribavir 400 mg BID or foscarnet.

    3. Graft pyelonephritis

      Fever, graft tenderness, pyuria: cultures, renally adjusted antibiotics, drain if obstructed.

    Over 1 year

    Adherence, trough, DSA, BK PCR, urine PCR, HbA1c, Doppler → biopsy with C4d, SV40, IF and EM.
    PTLD: mass, weight loss, high LDH → CT, tissue biopsy.

    By biopsy

    Chronic CNI toxicity: minimise CNI, never stop abruptly; mTOR inhibitor or belatacept (EBV-seropositive).
    Recurrent GN: ACE inhibitor or ARB + specific: FSGS PLEX × 9; aHUS eculizumab; MN rituximab.

    eGFR still falling: plan dialysis access and early re-listing.

    Exam trap

    Pulse steroids for SV40-positive tubulitis: that is BK; reduce immunosuppression.
    Fever with graft tenderness: graft pyelonephritis first; rejection rarely causes fever unless immunosuppression stopped.

Pocket check

Rapid recall

Order of the work-up?

Stabilise → Foley + fluids → Doppler → trough → BK/CMV PCR, DSA → biopsy.

Causes within 8 hours?

Hyperacute rejection, thrombosis, primary non-function, ischaemia-reperfusion.

Delayed graft function?

Dialysis within the first week; biopsy if beyond ~1–2 weeks.

Urine leak or lymphocele?

Fluid creatinine well above serum: leak. Like serum: lymphocele.

Biopsy safety?

Platelets >100, PT and APTT <1.2 × control, BP <140/90.

Presumptive BK nephropathy?

Plasma PCR >10,000 copies/mL: antimetabolite down at least 50%.

TCMR IA/IB?

Methylprednisolone 250–500 mg × 3–5 days; resistant: rATG.

Active ABMR?

PLEX 2–5 + IVIG 100–200 mg/kg after each, pulse steroid.

Donor unknown?

Anti-HLA antibody screen, not DSA; C4d substitutes on biopsy.

Three rules for every ladder?

Keep immunosuppression on; treat the biopsy; no response = re-biopsy, recheck trough, BK, DSA.

Next tabs: algorithms, spoken answer, viva questions.

Sources: KDIGO transplant recipients 2009; Banff 2019 and 2022; CCN 2023 ch 109; 2024 BK consensus.

🗣

Spoken approach

say this aloud
🧠 Self-test — say each step from its label, then tap it to check.
  1. Opening: This is graft dysfunction; I follow the KDIGO transplant-recipient chain: stabilise, exclude reversible causes, then biopsy before treating rejection.
  2. Stabilise: I treat hyperkalaemia, acidosis and overload and start dialysis if indicated, avoiding aggressive ultrafiltration; I continue immunosuppression.
  3. Time since transplant: Hours to week 1: thrombosis, hyperacute rejection, leak, ATN. Up to 12 weeks: acute rejection, CNI toxicity, obstruction, infection. Later: add chronic ABMR, TRAS, PTLD and non-adherence.
  4. History & exam: Adherence and missed doses, new interacting drugs, diarrhoea, fever, urine output, donor and induction; volume, graft tenderness, wound, drain and Foley.
  5. Pre- and post-renal: I flush the Foley, correct volume, and do Doppler ultrasound for thrombosis, stenosis, hydronephrosis and collections, sending drain creatinine if fluid leaks.
  6. Renal labs: Tacrolimus trough, urinalysis and culture, protein, plasma BK and CMV PCR, TMA screen and DSA, an anti-HLA screen if the donor is unknown.
  7. Diagnosis: Persistent unexplained rise: biopsy with C4d and SV40 once platelets are over 100; only now do I say TCMR, ABMR, BK, CNI toxicity or recurrence.
  8. Treatment & if it fails: TCMR: methylprednisolone 250-500 mg x 3-5 days, vascular or resistant: rATG. ABMR: plasma exchange + IVIG. BK: reduce immunosuppression. CMV: valganciclovir. No response: re-biopsy.
⚡

Quick reference

numbers at a glance
OrderStabilise/dialyse → Foley + volume → Doppler → trough → BK/CMV PCR, DSA → biopsy
Hours (within 8 h)Hyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion
DGFDialysis within first week; biopsy if beyond ~1-2 weeks or creatinine rises
Artery thrombosis0.1-2%, within 72 h, painless anuria
Urine leakDrain creatinine well above serum (often many times higher), lymphocele about equal to serum; Foley, stent 1-3 weeks
Tacrolimus targetMonth 1: 10-15 • to ~6 months: 8-12 • later: 6-8 (typical; centre- and regimen-dependent)
BKPeak 3-6 months; plasma PCR over 10,000 = presumptive → antimetabolite down at least 50%
TCMRMP 3-5 mg/kg (250-500 mg) x 3-5 d → rATG 1-1.5 mg/kg x 7-14 d
ABMRPLEX 2-5 + IVIG 100-200 mg/kg after each → rituximab 375 mg/m²
Biopsy safetyPlatelets over 100; PT and APTT under 1.2 x control; BP under 140/90
◈

Exam traps & pitfalls

where marks are lost
  • Jumping to biopsy before Foley, volume, Doppler and trough: KDIGO says exclude dehydration, obstruction and high CNI level first.
  • Treating creatinine with pulse steroids without a biopsy when one is available (Rec 6.1).
  • Stopping immunosuppression for DGF or for dialysis: continue it.
  • Calling every fever with graft tenderness rejection: graft pyelonephritis is the leading cause.
  • Pulsing steroids for SV40-positive tubulitis: that is BK, reduce immunosuppression.
  • Saying DSA when the donor is unknown: say anti-HLA antibody screen; C4d substitutes on biopsy.
  • Reading a high resistive index as rejection: it rises with ATN, thrombosis and hydronephrosis too.
  • Over-treating mild hydronephrosis: the graft ureter has no valve; renogram if unclear.
  • Forgetting non-adherence and interacting drugs as the trigger of late rejection.
📐

Guideline algorithm

the source this answer follows

Source: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients, Am J Transplant 2009;9(Suppl 3), Chapters 8 (p S27), 5 (p S19), 9 (p S30), 6 (p S21) and 13.1 (p S44), still the latest KDIGO transplant-recipient guideline; biopsy read by Banff 2019 Category 2 with the Banff 2022 additions; doses from Comprehensive Clinical Nephrology 2023 ch 109, Tables 109.1-109.2. This is the same verified chain used in our commercial-transplant, ABMR and TCMR topics. The time windows below are the graft-dysfunction-by-time differential from our TCMR topic.

StepWhat the guideline says
Rec 8.4We suggest including a kidney allograft ultrasound examination as part of the assessment of kidney allograft dysfunction. (2C)
Rec 5.1We recommend measuring CNI blood levels (1B), and suggest measuring at least … whenever there is a decline in kidney function that may indicate nephrotoxicity or rejection. (2C)
Ch 9 rationaleCauses of acute, reversible declines in GFR should be ruled out, including dehydration, urinary obstruction or acute CNI toxicity (by demonstrating high blood levels), before a biopsy is performed.
Rec 9.1We recommend kidney allograft biopsy when there is a persistent, unexplained increase in serum creatinine. (1C)
Rec 6.1We recommend biopsy before treating acute rejection, unless the biopsy will substantially delay treatment. (1C)
Rec 6.3We recommend corticosteroids for the initial treatment of acute cellular rejection. (1D)
Rec 6.3.2We suggest using lymphocyte-depleting antibodies or OKT3 for acute cellular rejections that do not respond to corticosteroids, and for recurrent acute cellular rejections. (2C)
Rec 6.4We suggest treating antibody-mediated acute rejection with one or more of the following alternatives, with or without corticosteroids (2C): plasma exchange; intravenous immunoglobulin; anti-CD20 antibody; lymphocyte-depleting antibody.
Rec 6.5For patients who have a rejection episode, we suggest adding mycophenolate if the patient is not receiving mycophenolate or azathioprine, or switching azathioprine to mycophenolate. (2D)
Rec 13.1.2We suggest reducing immunosuppressive medications when BKV plasma NAT is persistently greater than 10 000 copies/mL. (2D)
Time windows (TCMR topic)Week 1 - acute tubular necrosis, hyperacute/accelerated rejection, obstruction or urine leak, renal artery or vein thrombosis, volume contraction; under 12 weeks - acute rejection, CNI toxicity, obstruction, pyelonephritis or viral infection, interstitial nephritis, recurrent disease; over 12 weeks - add chronic allograft nephropathy, transplant renal artery stenosis and PTLD.
🧭

Algorithm 1 master approach diagram

graph TD;
A["Transplant recipient, creatinine rising or urine output falling"] --> B{"Hyperkalaemia, acidosis, overload or uraemia?"};
B -->|Yes| C["Urgent dialysis, gentle ultrafiltration, continue immunosuppression"];
B -->|No| D["Time since transplant ranks the causes, Algorithm 2"];
C --> D;
D --> E["Pre-renal: volume, sepsis, high CNI trough, vessels, Algorithm 3"];
D --> F["Post-renal: Foley, hydronephrosis, collection, leak, Algorithm 4"];
D --> G["Renal: trough, BK and CMV PCR, DSA, TMA screen, protein, Algorithm 6"];
E --> H{"Reversible cause found and creatinine back to baseline?"};
F --> H;
G --> H;
H -->|Yes| I["Treat the cause, recheck creatinine and trough"];
H -->|No, persistent unexplained rise| J["Graft biopsy with C4d and SV40, Banff"];
J --> K["Rejection, Algorithm 7"];
J --> L["Infection, BK or CMV, Algorithm 8"];
J --> M["CNI toxicity, TMA, recurrence, chronic injury, Algorithms 6 and 9"];
📌

Time since transplant

WindowThink firstFirst move
Within 8 hoursHyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion injuryDoppler now; absent flow = surgeon, re-exploration
Week 1ATN/DGF (commonest), hyperacute/accelerated rejection, obstruction or urine leak, artery or vein thrombosis (artery within 72 h), volume contractionFoley flush → fluid challenge → Doppler → biopsy if unexplained
Up to 12 weeksAcute rejection (TCMR usually after week 1, most often within 3-6 months), CNI toxicity, obstruction (2-10%, within 3 months), urine leak (first 3 months), pyelonephritis or viral infection, interstitial nephritis, recurrent disease (FSGS in the first month)Trough, Doppler, urine culture, BK/CMV PCR, DSA → biopsy
3-12 monthsBK nephropathy (over 90% within 12 months, peak 3-6 months), TCMR, CMV, TRAS (1-23%, usually first year), lymphocelePlasma BK PCR, CMV PCR, Doppler for stenosis, biopsy
Over 1 year (late)Non-adherence and de novo DSA → chronic active ABMR, chronic CNI toxicity, recurrent or de novo GN, TRAS, PTLD (median 18 months, graft 10-15%)Adherence, trough, DSA, BK PCR, proteinuria → biopsy
🧭

Algorithm 2 by time since transplant diagram

graph TD;
A["Graft dysfunction"] --> B{"Time since transplant"};
B -->|Within 8 hours| C["Hyperacute rejection, vascular thrombosis, primary non-function, ischaemia-reperfusion"];
C --> C1["Doppler now, absent flow means urgent surgical re-exploration"];
B -->|Week 1| D["ATN or DGF, accelerated rejection, obstruction or leak, thrombosis, volume contraction"];
D --> D1["Day-1 oliguria pathway, Algorithm 5"];
B -->|Up to 12 weeks| E["Acute rejection, CNI toxicity, obstruction, pyelonephritis or viral infection, interstitial nephritis, recurrent disease"];
E --> E1["Trough, Doppler, urine culture, BK and CMV PCR, DSA, then biopsy"];
B -->|3 to 12 months| F["BK nephropathy peak 3-6 months, TCMR, CMV, TRAS, lymphocele"];
F --> F1["Plasma BK PCR, CMV PCR, Doppler for stenosis, biopsy"];
B -->|Over 1 year| G["Non-adherence, de novo DSA, chronic active ABMR, chronic CNI toxicity, recurrence, TRAS, PTLD"];
G --> G1["Late pathway, Algorithm 9"];
📌

Pre renal renal post renal

BucketCauses in a graftClue / testAction
Pre-renalHypovolaemia, diarrhoea, sepsis, hypotension; CNI vasoconstriction (high trough); renal artery thrombosis; TRASVolume status, trough, Doppler; normal RI with falling urine output points to a haemodynamic causeCrystalloid challenge, stop nephrotoxins, fix the trough; TRAS: Doppler then MRI, angioplasty +/- stent
Post-renalBlocked or kinked Foley, ureteral obstruction (ischaemia up to 90%), urine leak, lymphocele or haematoma compressing the ureterFoley flush, ultrasound (over 90% sensitive; mild hydronephrosis often non-significant), renogram, drain creatinine, cystogramFoley, nephrostomy or stent, drain the collection, surgical repair if it fails
Renal - immunologicalHyperacute, TCMR, ABMR, mixed; recurrent GNDSA (anti-HLA screen if donor unknown), proteinuria, biopsy with C4dBy Banff: steroids, ATG, PLEX + IVIG; disease-specific for recurrence
Renal - toxicAcute or chronic CNI toxicity, CNI-associated TMA, interacting drugs (azoles, macrolides, non-DHP CCBs)Trough, platelets, LDH, haptoglobin, film; biopsy: isometric vacuolisation, arteriolar hyalinosis, striped fibrosisReduce CNI to target; TMA: reduce or switch the agent
Renal - infectiveGraft pyelonephritis, BK nephropathy, CMV, ATNUrine and blood cultures, plasma BK PCR, CMV PCR, SV40 on biopsyAntibiotics (drain if obstructed); BK: reduce immunosuppression; CMV: valganciclovir/ganciclovir
🧭

Algorithm 3 pre renal and vascular diagram

graph TD;
A["Suspected pre-renal or vascular cause"] --> B["Volume status, BP, diarrhoea, sepsis, new drugs"];
B --> C{"Hypovolaemic?"};
C -->|Yes| D["Crystalloid fluid challenge, stop nephrotoxins, reassess urine output and creatinine"];
C -->|No| E["Tacrolimus trough and Doppler ultrasound"];
D --> E;
E --> F{"Trough above target for this phase?"};
F -->|Yes| G["CNI vasoconstriction or toxicity, look for CYP3A4 inhibitors, reduce dose, recheck"];
F -->|No| H{"Doppler finding"};
H -->|Absent flow within 72 hours, painless anuria| I["Renal artery thrombosis, urgent surgery"];
H -->|Haematuria, oliguria, pain, no venous flow| J["Renal vein thrombosis, urgent surgery"];
H -->|High velocity at anastomosis, first year| K["TRAS, MRI then angioplasty with or without stent"];
H -->|Normal| L["Not pre-renal, go to post-renal and renal pathways"];
🧭

Algorithm 4 post renal and collections diagram

graph TD;
A["Falling urine output or rising creatinine"] --> B["Check and flush Foley catheter"];
B --> C["Graft ultrasound with Doppler"];
C --> D{"Finding"};
D -->|Hydronephrosis| E{"Significant or mild?"};
E -->|Mild, graft ureter has no valve| F["Renogram before acting"];
E -->|Significant| G["Nephrostomy or ureteral stent, then find the cause, ischaemic stricture commonest"];
D -->|Perigraft collection| H["Aspirate or drain fluid, creatinine vs serum, culture"];
H -->|Fluid creatinine well above serum| I["Urine leak, Foley at once, cystogram or renogram"];
I --> I1["Low volume: stent plus Foley 1-3 weeks and drain, high volume or failure: explore and reimplant"];
H -->|Creatinine like serum, weeks to months| J["Lymphocele, drain if it compresses ureter or vessels"];
H -->|Blood, early or after biopsy| K["Haematoma, usually resolves"];
H -->|Fever, CRP, positive culture| L["Abscess, drain plus antibiotics"];
D -->|Normal| M["Renal pathway, Algorithm 6"];
🧭

Algorithm 5 day 1 oliguria and dgf diagram

graph TD;
A["Day-1 oliguria or anuria after transplant"] --> B["Check and flush Foley catheter"];
B --> C{"Still oliguric?"};
C -->|Yes| D["Fluid challenge, reassess volume status"];
D --> E{"Still oliguric?"};
E -->|Yes| F["Renal Doppler ultrasound, vascular and urologic causes"];
F --> G{"Thrombosis, obstruction or leak?"};
G -->|Yes| H["Urgent surgical re-exploration or urologic intervention"];
G -->|No| I["Presumed ATN, delayed graft function if dialysis needed in week 1"];
I --> J["Continue immunosuppression, check CNI trough, dialysis as needed"];
J --> K{"Creatinine falling over days?"};
K -->|Yes| L["Supportive care, await recovery over days to weeks"];
K -->|No, rising or beyond 1-2 weeks| M["Biopsy for rejection on ATN, send CMV PCR"];
🧭

Algorithm 6 renal causes and biopsy diagram

graph TD;
A["Pre- and post-renal excluded"] --> B["Tacrolimus trough, urinalysis and culture, protein, plasma BK PCR, CMV PCR, DSA, platelets, LDH, haptoglobin, film"];
B --> C{"Clue"};
C -->|High trough| D["Reduce CNI to target, recheck creatinine, biopsy if no improvement"];
C -->|BK PCR over 10,000 or rising| E["BK pathway, Algorithm 8"];
C -->|CMV PCR positive with fever, leukopenia| F["CMV pathway, Algorithm 8"];
C -->|Low platelets, high LDH, schistocytes| G["TMA, CNI-related or antibody-mediated, biopsy"];
C -->|New heavy proteinuria| H["Recurrent or de novo GN, biopsy with IF and EM"];
C -->|Positive DSA or no clue| I["Biopsy"];
D --> I;
I --> J{"Safe to biopsy? Platelets over 100, PT and APTT under 1.2 x, BP under 140/90"};
J -->|Yes| K["Graft biopsy with C4d and SV40, Banff scoring"];
J -->|No| L["Correct first, or empirical pulse steroid if rejection likely, biopsy when safe"];
🪜

How to read the tests

FindingMeaning
Absent or reversed diastolic flow, no venous flowVascular thrombosis or severe rejection: urgent surgical review
Resistive indexAbout 0.6 normal, above 0.7 high; rejection, ATN, thrombosis and hydronephrosis all raise it, so it does not say which
High tacrolimus troughCNI toxicity likely: reduce and recheck; a true trough is 12 +/- 2 h after a twice-daily dose
Low or undetectable troughMissed doses or interaction: rejection risk is high
Plasma BK PCROver 1,000 copies/mL sustained beyond 2 weeks = probable; over 10,000 = presumptive BK nephropathy
Biopsy: tubulitis + interstitial inflammation, no C4d/DSATCMR IA/IB; intimal arteritis (v1/v2) = IIA/IIB; transmural arteritis = III
Biopsy: microvascular inflammation (g+ptc) + C4d or g+ptc at least 2 + DSAActive ABMR; with transplant glomerulopathy (cg over 0) = chronic active ABMR
Biopsy: intranuclear inclusions, SV40 positiveBK nephropathy: reduce immunosuppression, do not pulse steroids
Biopsy: isometric tubular vacuolisation / arteriolar hyalinosis, striped fibrosisAcute / chronic CNI toxicity
Biopsy: same lesion as the native kidneyRecurrent disease (FSGS, IgAN, MN, C3G, aHUS)
🧭

Algorithm 7 rejection treatment diagram

graph TD;
A["Biopsy shows rejection"] --> B{"Type"};
B -->|TCMR borderline with dysfunction or grade IA, IB| C["Methylprednisolone 250-500 mg IV daily x 3-5 days, optimise trough and adherence, add MMF"];
B -->|TCMR grade IIA, IIB or III| D["Pulse steroid plus rATG 1-1.5 mg/kg x 7-14 days"];
B -->|Active ABMR| E["Plasma exchange 2-5 sessions plus IVIG 100-200 mg/kg after each, plus pulse steroid"];
B -->|Mixed| F["Treat TCMR by grade plus plasma exchange, IVIG, consider rituximab"];
B -->|Chronic active ABMR| G["Optimise tacrolimus and MMF, adherence, no proven reversal"];
C --> H{"Creatinine improving?"};
D --> H;
E --> H;
H -->|Yes| I["Daily creatinine, CMV and PJP prophylaxis after ATG, BK plasma PCR monitoring, fix the trigger"];
H -->|No| J["Repeat biopsy, grade III or antibody component?"];
J --> K["Steroid-resistant TCMR: rATG, refractory ABMR: rituximab 375 mg/m2 or bortezomib in tertiary centre, both negative in RCTs"];
🧭

Algorithm 8 infection BK CMV pyelonephritis diagram

graph TD;
A["Graft dysfunction with infection clue"] --> B{"Which picture?"};
B -->|Fever, graft tenderness, pyuria| C["Graft pyelonephritis until proven otherwise"];
C --> C1["Urine and blood cultures, ultrasound for obstruction or abscess, renally adjusted antibiotics, drain if obstructed"];
C --> C2["Ask about stopped immunosuppression, rejection rarely causes fever otherwise"];
B -->|Asymptomatic rise, months 3-12, BK viraemia| D["Plasma BK PCR, biopsy two cores with medulla, SV40"];
D --> D1["Antimetabolite down at least 50%, recheck plasma PCR, expect a 10-fold fall by 4 weeks"];
D1 --> D2["No 10-fold fall at 4 weeks: stop antimetabolite, prednisone 5-10 mg/day, then lower CNI, tacrolimus trough about 5"];
D2 --> D3["Still rising: confirm reduction achieved, re-biopsy, no proven antiviral"];
B -->|Fever, leukopenia, diarrhoea, after ATG or D+/R-| E["Quantitative CMV PCR, endoscopy and biopsy if GI and PCR negative"];
E --> E1["Valganciclovir 900 mg twice daily, or IV ganciclovir 5 mg/kg q12h if severe, GFR-adjusted, reduce antimetabolite"];
E1 --> E2["Weekly PCR, at least 2 weeks until below threshold"];
E2 --> E3["No response after 2 weeks: UL97 and UL54 genotyping, maribavir 400 mg twice daily or foscarnet"];
🧭

Algorithm 9 late graft dysfunction diagram

graph TD;
A["Over 1 year: slow creatinine rise or new proteinuria"] --> B["Adherence, pill count, trough history, new drugs"];
B --> C["Doppler for obstruction and TRAS, trough, plasma BK PCR, DSA, urine PCR, HbA1c"];
C --> D["Graft biopsy with C4d, SV40, IF and EM"];
D --> E{"Biopsy"};
E -->|Chronic active ABMR| F["Optimise tacrolimus, MMF and steroid, adherence support"];
E -->|Chronic CNI toxicity| G["Minimise CNI, consider mTOR inhibitor or belatacept if EBV positive"];
E -->|Recurrent or de novo GN| H["ACE inhibitor or ARB plus disease-specific therapy"];
E -->|BK nephropathy| I["Stepwise immunosuppression reduction"];
C -->|Mass, weight loss, high LDH| J["PTLD work-up, CT, tissue biopsy"];
F --> K{"eGFR still falling?"};
G --> K;
H --> K;
K -->|Yes| L["Plan dialysis access and early re-listing"];
🧭

Algorithm 10 unknown donor or no biopsy diagram

graph TD;
A["Commercial transplant abroad or no biopsy access"] --> B["Stabilise, dialyse if needed, continue immunosuppression"];
B --> C["Doppler, tacrolimus trough, BK, CMV, HBV, HCV, HIV, TB screen"];
C --> D["Anti-HLA antibody screen, not DSA, because the donor is unknown"];
D --> E{"Biopsy possible and safe?"};
E -->|Yes| F["Biopsy, C4d substitutes for DSA in Banff"];
E -->|No, for example platelets 20| G["Methylprednisolone 500 mg IV daily x 3, correct platelets"];
G --> H{"Response by about 5 days?"};
H -->|Yes| I["Optimise maintenance, still biopsy when safe"];
H -->|No| J["Urgent biopsy or transfer, ATG for resistant TCMR, PLEX plus IVIG for ABMR"];
📌

Treatment by cause

CauseFirst-lineIf it fails
HypovolaemiaCrystalloid (preferred to albumin); stop nephrotoxinsLook again: Doppler, trough
DGF / ATNContinue immunosuppression, dialysis as needed, avoid aggressive UF; furosemide 100-200 mg only if hypervolaemicBiopsy if beyond ~1-2 weeks or rising creatinine (most centres at 7-10 days)
Artery / vein thrombosisUrgent surgical re-explorationGraft lost: back to dialysis, taper immunosuppression
Urine leakFoley at once, drain collection, stent + Foley 1-3 weeks; cystogram before catheter outNephrostomy, then explore and reimplant
ObstructionNephrostomy or stentSurgical urinary reconstruction
TRASDoppler then MRI, angioplasty +/- stentTransplant surgeon and interventional radiology review
CNI toxicityReduce to target trough, remove the interacting drug; titrate, never stop abruptlymTOR inhibitor or belatacept (EBV-seropositive)
CNI-associated TMAReduce or switch the offending CNICNI-free regimen
TCMR IA/IB, borderline with dysfunctionMethylprednisolone 3-5 mg/kg (250-500 mg) x 3-5 daysrATG 1-1.5 mg/kg x 7-14 days
TCMR IIA-IIIPulse steroid + rATG; valganciclovir prophylaxis 6 weeks afterRepeat biopsy
Active ABMRPLEX 2-5 sessions + IVIG 100-200 mg/kg after each, pulse steroidRituximab 375 mg/m² (largest RCT n=38 negative); bortezomib 1.3 mg/m² x 4 (BORTEJECT RCT negative), tertiary only
BK nephropathyAntimetabolite down at least 50% → stop it, with prednisone 5-10 mg/day → lower CNI (tacrolimus trough about 5); reducing the CNI first is equally acceptable (2024 BK consensus)Confirm reduction, re-biopsy; IVIG, cidofovir, leflunomide unproven
CMV diseaseValganciclovir 900 mg BID or IV ganciclovir 5 mg/kg q12h, GFR-adjusted; reduce antimetaboliteUL97/UL54 → maribavir 400 mg BID or foscarnet
Graft pyelonephritisCultures, renally adjusted antibiotics, drain if obstructedImage for obstruction, ureteric stricture or abscess
Recurrent FSGSPlasma exchange x 9, CNI, steroid, ACE inhibitor, no mTOR inhibitorRituximab 500 mg weekly x 4 or cyclophosphamide
Recurrent aHUS / MNEculizumab / rituximabSpecialist centre
⤴

Memorise treatment and escalation

Order of the work-up — Some Fluid Drains Through Plastic Bags: Stabilise (dialyse if needed, keep immunosuppression) → Foley flush + fluids → Doppler → Trough → PCR (BK, CMV) + DSA panel → Biopsy.

Causes and their ladders — the 6 Ps (first move → if it fails → last resort):

  1. Perfusion (pre-renal): crystalloid, stop nephrotoxins → look again: Doppler and trough. TRAS: Doppler → MRI → angioplasty ± stent.
  2. Pipes (surgical): thrombosis re-explore → graft lost: dialysis, taper immunosuppression. Leak Foley + drain + stent 1-3 weeks → nephrostomy → reimplant. Obstruction nephrostomy or stent → surgical reconstruction.
  3. Poison (CNI): trim to target trough and remove the interacting drug, never stop abruptly → switch to mTOR inhibitor or belatacept (EBV-seropositive). CNI-TMA: reduce or switch → CNI-free.
  4. Police (rejection) — biopsy first:
    • TCMR = S-A-R: Steroid pulse (MP 250-500 mg x 3-5 d) → ATG (1-1.5 mg/kg x 7-14 d) → Re-biopsy. Grade IIA-III: start at steroid + ATG.
    • ABMR = PIS, then R, then B: PLEX 2-5 + IVIG after each + Steroid → Rituximab → Bortezomib (tertiary only; both were negative in RCTs).
  5. Pathogens (infection):
    • BK = Half, Halt, then CNI: antimetabolite down at least 50% → no 10-fold fall at 4 weeks: stop it (prednisone 5-10 mg/day to avoid CNI monotherapy) → lower the CNI (tacrolimus trough about 5) → re-biopsy.
    • CMV = Val/Gan, cut, check resistance: valganciclovir or IV ganciclovir + reduce antimetabolite → UL97/UL54 → maribavir or foscarnet.
    • Pyelonephritis: cultures + antibiotics + drain if obstructed → image for stricture or abscess.
  6. Past disease (recurrence): FSGS plasma exchange → rituximab or cyclophosphamide; aHUS eculizumab; MN rituximab.

Three rules that cover every ladder: keep immunosuppression on (DGF and dialysis included) • treat the biopsy, not the creatinine • no response = re-biopsy and re-check trough, BK and DSA.

🎓

Examiner follow-ups

tap to reveal · self-test
Q1A transplant recipient has a rising creatinine. What is your approach?reveal
Stabilise and dialyse if needed, keep immunosuppression. Time since transplant ranks the causes. Then pre-renal (volume, trough, vessels), post-renal (Foley, ultrasound, collections) and renal (trough, BK and CMV PCR, DSA, TMA screen, protein). A persistent unexplained rise gets a biopsy before I treat rejection (KDIGO Rec 9.1 and 6.1).
Q2What causes graft dysfunction within 8 hours of surgery?reveal
Hyperacute rejection, vascular thrombosis, primary non-function or ischaemia-reperfusion injury. Doppler now; absent flow is a surgical emergency.
Q3Fresh transplant, good urine output, then oliguria on day 1. What do you do?reveal
Flush the Foley, give a fluid challenge, then renal Doppler for thrombosis, obstruction and leak. If clear, presumed ATN: continue immunosuppression, dialysis as needed, check the trough, and biopsy if it is prolonged beyond 1-2 weeks or creatinine rises.
Q4Define delayed graft function and slow graft function.reveal
DGF: need for dialysis within the first week. Slow graft function: creatinine above 3 mg/dL (about 265 umol/L) without dialysis in the first week.
Q5How do you tell a urine leak from a lymphocele?reveal
Drain or aspirate the fluid: fluid creatinine well above serum (often many times higher) is urine (usually first 3 months, at the ureterocystostomy); a lymphocele has fluid creatinine like serum, appears weeks to months later and is commoner with mTOR inhibitors. A cystogram or renogram shows the leak.
Q6Tacrolimus 16 at month 4 with creatinine 180 from 90. Is it toxicity?reveal
16 is above target for that phase, but I still exclude obstruction, vascular causes and rejection. I look for a CYP3A4 inhibitor, reduce the dose, recheck level and creatinine, and biopsy if it does not improve. Acute toxicity is isometric vacuolisation; chronic is arteriolar hyalinosis with striped fibrosis.
Q7Fever and graft tenderness one year after transplant?reveal
Infection until proven otherwise, graft pyelonephritis first. Rejection rarely causes fever unless immunosuppression was stopped, so I ask about adherence. Cultures, trough, BK and CMV PCR, ultrasound for hydronephrosis or collection, renally adjusted antibiotics, drain if obstructed.
Q8How do you differentiate BK nephropathy from TCMR on biopsy, and why does it matter?reveal
Both show tubulitis; BK has intranuclear inclusions and SV40-positive tubules, rejection is SV40-negative. It matters because BK needs less immunosuppression and pulse steroids deepen the problem; only DSA, microvascular inflammation with C4d, or creatinine rising as viral load falls moves me toward rejection.
Q9Biopsy shows Banff IIB TCMR. Treatment?reveal
Pulse methylprednisolone plus rATG 1-1.5 mg/kg for 7-14 days, then CMV and PJP prophylaxis with BK plasma PCR monitoring (there is no effective BK prophylaxis), and I fix the trigger (non-adherence, low trough); add mycophenolate if not on it (Rec 6.5).
Q10Active ABMR on biopsy. Treatment and evidence?reveal
Plasma exchange 2-5 sessions with IVIG 100-200 mg/kg after each, plus pulse steroid for any T-cell component. Refractory: rituximab 375 mg/m2 (largest RCT, n=38, negative) or bortezomib 1.3 mg/m2 x 4 in a tertiary centre, although the BORTEJECT RCT (late ABMR, n=44) was also negative. Evidence is low grade.
Q11You cannot biopsy (platelets 20 or no access). What do you do?reveal
Exclude non-rejection causes, then empirical methylprednisolone (500 mg daily x 3 when the biopsy is unsafe, or 250-500 mg x 3-5 days), therapeutic baseline immunosuppression, and biopsy when safe. About 60-70% respond within 5 days; no response means urgent biopsy, not more guessing.
Q12Commercial transplant abroad, unknown donor. What do you not say?reveal
Not DSA: the donor is unknown, so I send an anti-HLA antibody screen, and on biopsy C4d can substitute for DSA (Banff 2019). I also screen HBV, HCV, HIV and TB from an unscreened donor.
Q13Ten years out, slow creatinine rise and proteinuria. What are you thinking?reveal
Non-adherence with de novo DSA (60% vs 20% at 10 years) and chronic active ABMR, chronic CNI toxicity, recurrent or de novo GN, BK, TRAS. Adherence, trough, DSA, BK PCR, Doppler, then biopsy; ACE inhibitor or ARB for proteinuria, and plan dialysis access if eGFR keeps falling.
Q14When is the graft biopsy safe?reveal
Once obstruction, urinary sepsis, renal artery stenosis and toxic CNI levels are excluded, with platelets over 100, PT and APTT under 1.2 x control, BP under 140/90 and sterile urine.
📌

Go deeper

Each pathway has its own full case on NephroApp:

  • Delayed graft function / day-1 oliguria
  • Early surgical complications and urine leak
  • CNI toxicity and tacrolimus level problems
  • T-cell-mediated rejection and antibody-mediated rejection
  • Suspected rejection with no biopsy and commercial transplant abroad
  • BK virus nephropathy and CMV in transplant
  • Recurrent glomerular disease and PTLD
Practice & Recall
Reading Mode
Saved
🔖 My bookmarksBrowse all saved sections & notes
Share & Export

Your study progress

    Every section is studied.

    🎙️
    Podcast Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step
    0:00 0:00
    Podcast
    Consultant Viva Simulator

    Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step

    💡 Screen-Share Drill: With Gemini Live active, say: "Read my screen and examine me on this topic"
    EXAMINER BRIEF & MARKING SCHEME (17 CRITERIA) 🖥️ Screen-Share Ready
    ROLE
    You are examining me for the nephrology CONSULTANT viva. It is an oral exam on Zoom: two sittings, two examiners, about six questions each. One examiner is gentle; the second wants detail everywhere.
    
    WHAT IS ON MY SCREEN
    A study app. Each topic shows a numbered "Say this" model answer and an amber "examiner wants" list — those are the exact keywords real examiners listened for. Use that list as your marking scheme.
    
    RULES — follow these strictly
    1. Ask ONE question out loud, then STOP and wait. Do not speak again until I have finished answering.
    2. Never read the model answer or the keyword list aloud before I answer, and never hint. If I stall, say "take your time" — nothing else.
    3. Expect 60-90 seconds from me. Past two minutes, cut me off politely and move on, exactly as a real examiner would.
    4. When I stop, mark me: go through the on-screen keyword list and tell me which ones I actually said and which I missed. Quote the missed ones word for word.
    5. Then ask ONE follow-up — a "why", a dose, a trial name, a guideline year, or a twist to the case. This is where the real exam is won or lost.
    
    HOW TO MARK ME
    - Be strict and unsentimental. "Manage appropriately", "treat the underlying cause", "I would refer" are not answers — challenge them immediately.
    - A missing dose, threshold, trial name or guideline version is a lost mark. Say so out loud.
    - Never praise fluency that carries no content.
    - If I say something factually wrong, correct it on the spot, precisely, and tell me what the right figure is.
    - Do not soften your scoring to be encouraging. I need the real number.
    
    LANGUAGE — this matters, follow it exactly
    - Ask every question in ENGLISH. The real exam is in English and I need to practise hearing it that way.
    - I will answer in English, sometimes mixed with Arabic. Judge the medicine, not the language.
    - BUT when you MARK me — the score, what I missed, the feedback, the final summary — speak EGYPTIAN COLLOQUIAL ARABIC (عامية مصرية).
    - Inside that Arabic, keep every medical term, drug name, dose, trial name, guideline and threshold in ENGLISH. Never translate them into Arabic.
    - Give the score in this exact shape:
      "انت جبت ٥ من ١٠ علشان نسيت treatment of edema with diuretics، ونسيت تدي المريض statin، وماقلتش anti-PLA2R titre."
    - Then say, still in Egyptian Arabic, إيه اللي كان لازم تقوله بالظبط — with the English terms in place.
    
    AFTER EVERY MARK — always end your turn with this, in Egyptian Arabic, then STOP and wait:
      "تمام. نعدّي لسؤال تاني؟ ولا تحب نتناقش أكتر في السؤال ده؟ ولا عندك اعتراض على حاجة؟"
    Never move to the next question until I answer that.
    If I object to something you said: take it seriously and re-check your own claim before you defend it — I may well be right, and the guideline may have moved. If you were wrong, say so plainly and give me the correct figure. If I am the one who is wrong, do NOT back down to be polite: hold your position and tell me the evidence — the guideline, the trial, the number. Caving to a confident candidate is exactly how a wrong fact survives to the real exam.
    
    THIS SESSION
    Drill me on ONE topic only: Approach to a kidney-transplant recipient with graft dysfunction: every timeframe, pre-renal, renal or post-renal, rejection or infection, step by step.
    The marking scheme for this topic is:
    1. Opening: This is graft dysfunction; I follow the KDIGO transplant-recipient chain: stabilise, exclude reversible causes, then biopsy before treating rejection.
    2. Stabilise: I treat hyperkalaemia, acidosis and overload and start dialysis if indicated, avoiding aggressive ultrafiltration; I continue immunosuppression.
    3. Time since transplant: Hours to week 1: thrombosis, hyperacute rejection, leak, ATN. Up to 12 weeks: acute rejection, CNI toxicity, obstruction, infection. Later: add chronic ABMR, TRAS, PTLD and non-adherence.
    4. History & exam: Adherence and missed doses, new interacting drugs, diarrhoea, fever, urine output, donor and induction; volume, graft tenderness, wound, drain and Foley.
    5. Pre- and post-renal: I flush the Foley, correct volume, and do Doppler ultrasound for thrombosis, stenosis, hydronephrosis and collections, sending drain creatinine if fluid leaks.
    6. Renal labs: Tacrolimus trough, urinalysis and culture, protein, plasma BK and CMV PCR, TMA screen and DSA, an anti-HLA screen if the donor is unknown.
    7. Diagnosis: Persistent unexplained rise: biopsy with C4d and SV40 once platelets are over 100; only now do I say TCMR, ABMR, BK, CNI toxicity or recurrence.
    8. Treatment & if it fails: TCMR: methylprednisolone 250-500 mg x 3-5 days, vascular or resistant: rATG. ABMR: plasma exchange + IVIG. BK: reduce immunosuppression. CMV: valganciclovir. No response: re-biopsy.
    9. Exam trap: Jumping to biopsy before Foley, volume, Doppler and trough: KDIGO says exclude dehydration, obstruction and high CNI level first.
    10. Exam trap: Treating creatinine with pulse steroids without a biopsy when one is available (Rec 6.1).
    11. Exam trap: Stopping immunosuppression for DGF or for dialysis: continue it.
    12. Exam trap: Calling every fever with graft tenderness rejection: graft pyelonephritis is the leading cause.
    13. Exam trap: Pulsing steroids for SV40-positive tubulitis: that is BK, reduce immunosuppression.
    14. Exam trap: Saying DSA when the donor is unknown: say anti-HLA antibody screen; C4d substitutes on biopsy.
    15. Exam trap: Reading a high resistive index as rejection: it rises with ATN, thrombosis and hydronephrosis too.
    16. Exam trap: Over-treating mild hydronephrosis: the graft ureter has no valve; renogram if unclear.
    17. Exam trap: Forgetting non-adherence and interacting drugs as the trigger of late rejection.
    
    Ask me an opening case stem on this topic, mark me against that list, then escalate: doses, the trials by name, the pitfalls, and one "what if" twist to the case. Four to six exchanges.
    
    AT THE END, in Egyptian Arabic with the medical terms in English: قولّي أكتر حاجة ممكن تضيع مني درجات في الموضوع ده في الامتحان الحقيقي، وقول بصوت عالي نسخة الـ ٦٠ ثانية اللي كان المفروض أقولها.
    
    Begin when I say "ready".
    Consultant Viva · Egyptian Arabic Marking

    Report a mistake

    Please sign in to report a mistake, so we can ask you if we need more details.

    Sign in

    Liked this topic?

    Every exam case is built the same way. Subscribe to open all of them.

    See the plans →
    Home All Topics Contact Us Terms of Service Privacy Policy Refund Policy Facebook YouTube Monawib

    Tools: Nephrology tools · Radiology

    Disclaimer: NephroApp is an independent educational platform and is not affiliated with, endorsed by, or sponsored by any licensing authority, examination provider, or textbook publisher. The MCQ Bank provides exam-style practice for educational purposes.

    Nephroapp© 2026. All rights reserved.

    Made with by Dr. Hossam Abohassan